Status:
UNKNOWN
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Conditions:
Clostridium Difficile Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Data on the seroprevalence of antibodies to Clostridioides difficile surface proteins and toxins are scarce. In 1983, Viscidi et al. showed that antibodies to C. difficile toxins A and B were detecte...
Eligibility Criteria
Inclusion
- Adult patient (≥ 18 years) hospitalized in targeted short-stay (MCO) and long-stay (LTC) services for each of the three identified regions
- French-speaking patient
- Patient affiliated to the social security system or, failing that, to another health insurance system
- Patient able to give free, informed and written consent
Exclusion
- History of blood transfusion, vascular filling, dialysis or polyvalent immunoglobulin infusion.
- Patient deprived of liberty
- Patient under court protection
- Patient in an emergency situation
- Patients unable to give personal consent, including adults under guardianship
Key Trial Info
Start Date :
November 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
840 Patients enrolled
Trial Details
Trial ID
NCT05192148
Start Date
November 30 2021
End Date
December 30 2024
Last Update
April 7 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Paris Saint-Joseph
Paris, France, 75014
2
Hôpital Sainte-Marie Paris
Paris, France, 75014
3
Centre de SSR Pierre Chevalier
Toulon, France
4
Hôpital d'Instruction des Armées Sainte Anne,
Toulon, France